Page 18 - Recursion Pharmaceuticals News Today

These two biotech stocks hold enormous potential.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the biggest stories of the year has been the rise of AI in every industr...

Wood is moving away from fintech and Internet names like COIN stock. She's now favoring genomics and artificial intelligence companies.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $6.72, for a total transaction of $76,923.84. Following the completion of the sale, the director now owns 7,395,973 shares of the company’s […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price traded down 3.9% during trading on Monday . The stock traded as low as $6.50 and last traded at $6.59. 413,519 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 3,311,862 shares. The stock had previously closed at […]

Cathie Wood's Ark Invest has been boosting its bets in biotechnology lately, one of several disruptive sectors that Ark grants investors exposure to. Ark's…

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares rose 5.8% during mid-day trading on Tuesday . The stock traded as high as $6.92 and last traded at $6.91. Approximately 2,910,226 shares changed hands during mid-day trading, a decline of 13% from the average daily volume of 3,335,453 shares. The stock had previously closed at […]

Scaling up means having more power to bring to bear on core activities.

It's time to get constructive on mid-cap tech stocks, according to Karen Kharmandarian, senior portfolio manager at Thematics Asset Management.

The popular growth investor keeps adding to some of her favorite stocks.